Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage

Campanati, Anna; Martina, Emanuela; Giuliodori, Katia; Bobyr, Ivan; Consales, Veronica; Offidani, Annamaria

doi:10.1111/dth.12841

Cited by 21 publications

(28 citation statements)

References 18 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, total lesions were reduced in the active group at 3 and 6 months, respectively, as well as after BTX-B in an open setting in the former placebo group. Our pilot study confirms previous case reports [ 14 – 17 ] with a positive outcome of BTX treatment in HS and encourages further interventional studies.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

2020

View full text Add to dashboard Cite

Background Botulinum toxin (BTX) is a potent neurotoxin with a long history of therapeutic application in neurological and dermatological conditions, with a strong efficacy and safety profile. Objective Our aim was to assess whether intradermal injection with BTX-B is an effective treatment for hidradenitis suppurativa (HS). Methods Twenty patients with HS stage I-III disease, according to Hurley's classification, were consecutively included for treatment with either a placebo or BTX-B. At the next intervention after 3 months, all participants received the active substance and another follow-up at 6 months. The primary outcome was quality of life, measured using the Dermatology Life Quality Index (DLQI), while secondary outcomes were the visual analogue scale (VAS) for pain in the worst boil and HS-related impairment of general health (VAS), as well as changes in physician-reported disease activity assessed as the number of total lesions, and reported adverse effects of treatment. Results The DLQI improved from a median of 17 at baseline to 8 at 3 months in the BTX-B group, compared with a reduction from 13.5 to 11 in the placebo group (p <0.05). Improvement of the patients' own ratings of symptoms and a reduction in total lesions supplemented the primary outcome. Fifty-five percent of the study population reported some degree of hyperhidrosis. Conclusion BTX-B improves the quality of life in patients with HS. Furthermore, comorbidity between HS and hyperhidrosis is suggested. Trial Registration ClinicalTrials.gov identifier: NCT03103074.

show abstract

Section: Discussionsupporting

confidence: 90%

“…Five patients have previously received BTX-A injections for HS, with a positive outcome [14][15][16][17], whereas a study performed in five HS patients reported improvement in the Dermatology Life Quality Index (DLQI), but not for the number of nodules or VAS for pain [18].…”

Section: Introductionmentioning

confidence: 99%

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

2020

View full text Add to dashboard Cite

show abstract

“…Given the apocrine distribution of HS, we hypothesized that hyperhidrosis could be a comorbidity that contributes to disease activity and morbidity. This hypothesis was supported by 5 case reports [1][2][3][4][5] demonstrating the excellent response of HS in 6 patients (of whom 3 demonstrated clinical remission) who were treated with botulinum toxin A (BoNT-A), a treatment for hyperhidrosis approved by the U.S. Food and Drug Administration. Half of these patients presented with hyperhidrosis or increased sweat production.…”

Section: Hyperhidrosis Affects Quality Of Life In Hidradenitis Suppurmentioning

confidence: 86%

“…We therefore sought to confirm the efficacious treatment of HS by BoNT-A, as demonstrated by the 5 case reports. [1][2][3][4][5] To investigate this, we conducted a prospective analysis to assess the effectiveness of one-time treatment of BoNT-A (100 units, 2.5 units per 1.5 cm) in 5 patients with HS at the Stanford Department of Dermatology. All patients were female and endorsed excessive sweating, with an average age of 38.6 years and Hurley stages I to III.…”

Section: Hyperhidrosis Affects Quality Of Life In Hidradenitis Suppurmentioning

confidence: 99%

Hyperhidrosis affects quality of life in hidradenitis suppurativa: A prospective analysis

Hua

Kuo

Cho

et al. 2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…She received an injection every 3 months (four times thus far), which had significantly helped alleviate her pain and curbed the progress of her HS by resolving abscesses and healing draining sinuses. Campanati et al [155] investigated the potential therapeutic role of BoNT-A in HS by treating 2 patients. The first patient, a 23-year-old woman, suffering from axilliary HS, was treated with 50 U of BoNT-A per axilla while the second patient, a man of 50 -year-old with a HS of the groin and inner thighs, was treated with 100 U of BoNT-A for each side.…”

Section: Hidradenitis Suppurativamentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

Self Cite

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Two cases of Hidradenitis suppurativa and botulinum toxin type a therapy: A novel approach for a pathology that is still difficult to manage

Cited by 21 publications

References 18 publications

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

Hyperhidrosis affects quality of life in hidradenitis suppurativa: A prospective analysis

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Contact Info

Product

Resources

About